Keith H. Gibson

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 559 citations · Full text

Molecular Pharmacology, Drug Targeting, Oncology +10

New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties and structure-activity relationships of 2-alkylbenzimidazole derivatives

Andrew P. Thomas, C. Allott, Keith H. Gibson et al. · Journal of Medicinal Chemistry · 1992 · 91 citations · Full text

ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT

J.R. Woodburn, Andrew Barker, Keith H. Gibson et al. · Journal of Immunotherapy · 1997 · 66 citations

Novel Therapy, Medicine, Theatre +14

Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines

Keith H. Gibson, Walter Grundy, Andrew A. Godfrey et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 55 citations

Signaling Pathway, Medicine, Receptor Tyrosine Kinase +9

Identification of the hatching factor of the barnacle as the novel eicosanoid 10,11,12-trihydroxy-5,8,14,17-eicosatetraenoic acid

Thomas L Holland, J. Malcolm East, Keith H. Gibson et al. · Prostaglandins · 1985 · 50 citations

Biology, Natural Sciences, Biosynthesis +1